Related Experiment Video

Updated: May 4, 2026

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice
06:39

Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice

Published on: April 13, 2015

14.8K

The relationship between serum bilirubin concentration and coronary slow flow

Mehmet Demir1, Canan Demir, Selvi Coşar

  • 1Yaseminpark sit 4E D11, Osmangazi 16100, Bursa, Turkey.

Therapeutic Advances in Cardiovascular Disease
|December 12, 2013
PubMed

Insights

Serum bilirubin levels were significantly lower in patients with coronary slow flow (CSF) compared to controls. This finding suggests a potential link between bilirubin and the pathophysiology of CSF.

Area of Science:

  • Cardiology
  • Biochemistry

Background:

  • The exact causes of coronary slow flow (CSF) remain unclear, with potential factors including arteritis, endothelial dysfunction, and atherothrombosis.
  • Elevated serum bilirubin is known to possess anti-inflammatory and anti-proliferative effects on vascular smooth muscle cells, and is linked to cardiovascular disease.
  • The specific association between serum bilirubin levels and CSF has not been previously established.

Purpose of the Study:

  • To investigate the relationship between serum bilirubin concentrations and coronary slow flow (CSF).
  • To compare serum bilirubin levels in patients diagnosed with CSF against a control group.

Main Methods:

  • The study involved 50 patients with CSF and 30 healthy controls.
  • Standard biochemical tests, complete blood counts (including leukocyte, hemoglobin, hematocrit, and platelet counts) were performed on all participants.
  • Coronary angiography was utilized for patient diagnosis.

Main Results:

  • No significant differences in basic demographic characteristics were observed between the CSF and control groups.
  • CSF patients exhibited significantly lower levels of total, direct, and indirect serum bilirubin compared to controls (p < 0.001 for all).

Conclusions:

  • This study demonstrates a significant association between reduced serum bilirubin levels and the presence of coronary slow flow (CSF).
  • Lower serum bilirubin may play a role in the underlying mechanisms of CSF.
Abstract

Keywords:
bilirubincoronary slow flowendothelial dysfunctioninflammationthrombosis

More Related Videos

Author Spotlight: Improved Localization and Monitoring of Coronary Flow Reserve Using Modified PLAX View in Mice05:07

Author Spotlight: Improved Localization and Monitoring of Coronary Flow Reserve Using Modified PLAX View in Mice

Published on: August 25, 2023

2.2K
Intra-cardiac Side-Firing Light Catheter for Monitoring Cellular Metabolism using Transmural Absorbance Spectroscopy of Perfused Mammalian Hearts08:51

Intra-cardiac Side-Firing Light Catheter for Monitoring Cellular Metabolism using Transmural Absorbance Spectroscopy of Perfused Mammalian Hearts

Published on: May 12, 2019

8.8K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Time Course of Drug Effect01:14

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.6K
Drug Concentration Versus Time Correlation01:15

Drug Concentration Versus Time Correlation

The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
3.0K
Autoregulation of Blood Flow01:17

Autoregulation of Blood Flow

Autoregulation mechanisms are characterized by their inherent capacity for self-regulation without necessitating specific nervous stimulation or endocrine control. These mechanisms facilitate the adjustment of blood flow and, therefore, perfusion specific to each tissue region. This self-regulation encompasses chemical signals and myogenic controls.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation....
10.0K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K